These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 8033371

  • 1. Effect of different treatment regimes on linear growth and final height in beta-thalassaemia major.
    De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B.
    Clin Endocrinol (Oxf); 1994 Jun; 40(6):791-8. PubMed ID: 8033371
    [Abstract] [Full Text] [Related]

  • 2. Management of puberty for optimal auxological results in beta-thalassaemia major.
    Caruso-Nicoletti M, De Sanctis V, Cavallo L, Raiola G, Ruggiero L, Skordis N, Wonke B, International Workshop on Management of Puberty for Optimum Auxological Results.
    J Pediatr Endocrinol Metab; 2001 Jul; 14 Suppl 2():939-44. PubMed ID: 11529399
    [Abstract] [Full Text] [Related]

  • 3. Growth and puberty in thalassemia major.
    Saka N, Sükür M, Bundak R, Anak S, Neyzi O, Gedikoğlu G.
    J Pediatr Endocrinol Metab; 1995 Jul; 8(3):181-6. PubMed ID: 8521192
    [Abstract] [Full Text] [Related]

  • 4. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
    Soliman AT, Yassin MA, De Sanctis V.
    Acta Biomed; 2018 Feb 16; 89(2-S):27-32. PubMed ID: 29451226
    [Abstract] [Full Text] [Related]

  • 5. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
    Cavallo L, Gurrado R, Zecchino C, Manolo F, De Sanctis V, Cisternino M, Caruso-Nicoletti M, Galati M.
    J Pediatr Endocrinol Metab; 1998 Feb 16; 11 Suppl 3():845-9. PubMed ID: 10091155
    [Abstract] [Full Text] [Related]

  • 6. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb 16; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 7. Growth, puberty and endocrine function in beta-thalassaemia major.
    Low LC.
    J Pediatr Endocrinol Metab; 1997 Feb 16; 10(2):175-84. PubMed ID: 9364350
    [Abstract] [Full Text] [Related]

  • 8. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.
    Viprakasit V, Tanphaichitr VS, Mahasandana C, Assteerawatt A, Suwantol L, Veerakul G, Kankirawatana S, Pung-Amritt P, Suvatte V.
    J Med Assoc Thai; 2001 Jul 16; 84(7):929-41. PubMed ID: 11759973
    [Abstract] [Full Text] [Related]

  • 9. Growth and pubertal development in transfusion-dependent children and adolescents with thalassaemia major and sickle cell disease: a comparative study.
    Soliman AT, elZalabany M, Amer M, Ansari BM.
    J Trop Pediatr; 1999 Feb 16; 45(1):23-30. PubMed ID: 10191589
    [Abstract] [Full Text] [Related]

  • 10. Growth and puberty and its management in thalassaemia.
    De Sanctis V.
    Horm Res; 2002 Feb 16; 58 Suppl 1():72-9. PubMed ID: 12373018
    [Abstract] [Full Text] [Related]

  • 11. Growth and management of short stature in thalassaemia major.
    Theodoridis C, Ladis V, Papatheodorou A, Berdousi H, Palamidou F, Evagelopoulou C, Athanassaki K, Konstantoura O, Kattamis C.
    J Pediatr Endocrinol Metab; 1998 Feb 16; 11 Suppl 3():835-44. PubMed ID: 10091154
    [Abstract] [Full Text] [Related]

  • 12. The Effect of Blood Transfusion on Growth of Patients with Hb E/β-Thalassemia.
    Chuansumrit A, Sirachainan N, Kitpoka P, Kadegasem P, Songdej D, Sasanakul W, Wongwerawattanakoon P.
    Hemoglobin; 2019 Feb 16; 43(4-5):264-272. PubMed ID: 31760834
    [Abstract] [Full Text] [Related]

  • 13. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major.
    Richardson ME, Matthews RN, Alison JF, Menahem S, Mitvalsky J, Byrt E, Harper RW.
    Aust N Z J Med; 1993 Dec 16; 23(6):656-61. PubMed ID: 8141693
    [Abstract] [Full Text] [Related]

  • 14. Growth deficiency in polytransfused beta-thalassaemia patients is not growth hormone dependent.
    Cavallo L, Gurrado R, Gallo F, Zacchino C, De Mattia D, Tatò L.
    Clin Endocrinol (Oxf); 1997 Jun 16; 46(6):701-6. PubMed ID: 9274700
    [Abstract] [Full Text] [Related]

  • 15. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 16; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 16. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.
    Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ.
    N Engl J Med; 1990 Sep 13; 323(11):713-9. PubMed ID: 2388669
    [Abstract] [Full Text] [Related]

  • 17. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S.
    Cochrane Database Syst Rev; 2005 Oct 19; (4):CD004450. PubMed ID: 16235363
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb 19; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 20. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
    De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC, Italian Working Group on Endocrine Complications in Non-Endocrine Diseases.
    J Pediatr Endocrinol Metab; 2006 Apr 19; 19(4):471-80. PubMed ID: 16759032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.